Skip to main content

Advertisement

Table 1 Correlation of miR-126 expression with clinicopathological features of PCa patients

From: Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy

Clinicopathological features Cases No (n, %) miR-126 expression status P
Low (n, %) High (n, %)
Age     
<70 70 (54.69) 39 (55.71) 31 (44.29) NS
≥70 58 (45.31) 29 (50.00) 29 (50.00)
Preoperative PSA     
<4 ng/mL 3 (2.34) 0 (0) 3 (100.00) 0.003
4-10 ng/mL 35 (27.34) 7 (20.00) 28 (80.00)
>10 ng/mL 90 (70.31) 61 (67.77) 29 (32.23)  
Gleason score     
4-6 62 (48.44) 31 (50.00) 31 (50.00) NS
7 30 (23.44) 19 (63.33) 11 (36.67)
8-10 36 (28.13) 18 (50.00) 18 (50.00)  
Pathological stage     
T1 72 (56.25) 22 (30.56) 50 (69.44) 0.001
T2/T3 56 (43.75) 46 (82.14) 10 (17.86)
Lymph node metastasis     
Negative 106 (82.81) 47 (44.34) 59 (55.66) 0.006
Positive 22 (17.19) 21 (95.45) 1 (4.55)
Angiolymphatic invasion     
Negative 110 (85.94) 50 (45.45) 60 (54.55) 0.001
Positive 18 (14.06) 18 (100.00) 0 (0)
Surgical margin status     
Negative 108 (84.38) 56 (51.85) 52 (48.15) NS
Positive 20 (15.62) 12 (60.00) 8 (40.00)  
  1. Note: ‘NS’ refers to the difference without statistic significance.